Brand name: Regkirona TM
Active ingredients: regdanvimab
What it is used for
REGKIRONA has provisional approval for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19 (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).,The decision has been made on the basis of short term efficacy and safety data. Continued approval of this indication depends on the evidence of longer term efficacy and safety from assessment.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Shelf lifetime is 12 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
REGKIRONA is a sterile, clear to opalescent and colourless to pale yellow solution.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient regdanvimab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
